chitosan and plga microspheres as drug delivery ... - UniCA Eprints

More documents

Recommendations

Info

7. RFP Loaded PLGA Coated Chitosan Microspheres Obtained by WSD Method7.2.3. Surface ChargeZeta potential of microparticles differed significantly between uncoated PLGA and chitosancoatedPLGA microspheres (Table 7.2). Chitosan coating shifted the negative zeta potential ofpure PLGA microspheres to positive values, in relation to the used chitosan concentration.Increasing chitosan concentrations shifted the zeta potential from negative to highly positivevalues, as a consequence of the increasing amount of free ionizable amino groups. But zetapotential is also affected by the presence of RFP. In fact RFP encapsulated microparticlesshowed an increased zeta potential value. For instance, encapsulation of RFP shifted the zetapotential of uncoated PLGA particles from 2.80mV to -4.80 mV, whereas for chitosan-coatedparticles the zeta potential values changed from 4mV to 14mV, and from 19mV to 37mV forthe lowest chitosan concentration and the highest chitosan concentration respectively (Table7.2). It means that the zeta potential of the PLGA particles was affected by chitosanconcentration in the external phase.7.2.4. Entrapment Efficiency (E%)Figure 3 shows encapsulation efficiency (E%) of prepared microspheres. In the present part ofthe work the influence of chitosan coating concentration on the RFP entrapment in PLGAcoated chitosan microspheres was evaluated. The presence of chitosan coating onmicrospheres enhanced E%, which increased as chitosan concentration increased.In fact the highest E% were found for formulations with the highest amount of chitosan (0.5%and 0.75%). It has been reported that added hydrophilic polymers to primary emulsion as astabilizer could prevent loss of drug from the external phase.The presence of chitosan on particle surface is probably capable of preventing drug leakagesduring preparation but in particular during purification process (273).Figure 7.2 also shows that freeze-drying of microparticles did not result in statisticallyrelevant RFP leakage from any of the prepared microspheres.110
7. RFP Loaded PLGA Coated Chitosan Microspheres Obtained by WSD Method10080% RFP6040200No chit 0,1% chit 0,25% chit 0,5% chit 0,75% chitE% before FD E% after FDFigure 7.2: Entrapment Efficiency (E%) of Rfp-Loaded Plga Coated ChitosanMicrosferes7.2.5. Nebulization Studies of Chitosan MicrospheresNebulization studies carried out to evaluate stability and suitability of chitosan coated PLGAparticles for pulmonary/nasal administration.Nebulization led to a reduction of mean particle diameter, but not a reduction of P.I.These results demonstrate that the prepared microspheres had a multimodal distribution andthat nebulization led to a separation of the particles in all the three stages of the usedimpinger.Table 7.3: Particle Size of RFP-Loaded PLGA Coated Chitosan Microspheres Beforeand After NebulizationFormulationParticle Size (nm± SD)Before nebulizationP.I ± SDParticle Size(nm ± SD)After nebulizationP.I ± SDNo Chit. 2535 ± 58,01 0.506 ± 0,055 1463 ± 50,33 0,637 ± 0,0180,1% Chit. 2900 ± 59.54 0.571 ± 0.018 1746 ± 25,16 0,558 ± 0,0390,25% Chit. 2807 ± 85.89 0.459 ± 0.053 1786 ± 38,15 0,523 ± 0,0840,5% Chit. 2567 ± 19.76 0.494 ± 0.059 1700 ± 32,28 0,754 ± 0,0920,75% Chit. 1407 ± 51.23 0.392 ± 0.020 1266 ± 32,14 0,756 ± 0,098111
Page 1:
European Union Ministero dell’Uni
Page 5 and 6:
Table Of Contents1. GENERAL INTRODU
Page 7:
7.1.4. Release Studies/Stability St
Page 10 and 11:
1. General Introduction1.1. Pulmona
Page 12 and 13:
1. General Introductionmucosa, and
Page 14 and 15:
1. General Introductionis the fact
Page 16 and 17:
1.3. Lung Anatomy1. General Introdu
Page 18 and 19:
1. General Introductionhighly vascu
Page 20 and 21:
201. General Introductionliquid (84
Page 22 and 23:
1. General IntroductionAerosol size
Page 24 and 25:
1. General Introductionof numerous
Page 26 and 27:
1. General Introductionintermittent
Page 28 and 29:
1. General Introductionsphere prepa
Page 30 and 31:
1. General Introductionit, respecti
Page 32 and 33:
1. General Introductionthe subject
Page 34 and 35:
1. General IntroductionA. zahoor et
Page 36 and 37:
2. Chitosan And PLGA2.1. Chitosan a
Page 38 and 39:
2. Chitosan And PLGAfor the prepara
Page 40 and 41:
2. Chitosan And PLGAmainly controll
Page 42 and 43:
2. Chitosan And PLGAAt present, a n
Page 44 and 45:
2. Chitosan And PLGAneed to be a go
Page 46 and 47:
2. Chitosan And PLGAdichloromethane
Page 49 and 50:
3. Aim of the Work49
Page 51:
3. Aim of the WorkBiodegradable mic
Page 54 and 55:
4. RFP Loaded Chitosan Microspheres
Page 56 and 57:
Page 58 and 59:
Page 60 and 61: 4. RFP Loaded Chitosan Microspheres
Page 71 and 72: 5. Rifampicin Loaded ChitosanMicros
Page 83: 5. RFP Loaded Chitosan Microspheres
Page 86 and 87: 6. RFP Loaded PLGA Microspheres Pre
Page 100 and 101: 100
Page 102 and 103: 7. RFP Loaded PLGA Coated Chitosan
Page 118 and 119: 118
Page 120 and 121: 8. Final Discussion and Conclusions
Page 122 and 123: 9. References9. References1. Fred S
Page 124 and 125: 9. References40. Wayne L.G., Good R
Page 126 and 127: 1269. References88. Carpenter R.L.
Page 128 and 129: 1289. References135. Fukushima S.;
Page 130 and 131: 9. References173. Zeng X.M., Martin
Page 132 and 133: 9. References219. Berthold A., Crem
Page 134: 9. Referencesmediates target gene e
show all

chitosan and plga microspheres as drug delivery ... - UniCA Eprints

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?